Biosimilar Pharmaceuticals

Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
BACKGROUND: The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is …
Kristin K. Jørgensen, Guro L. Goll, Joe Sexton, Nils Bolstad, Inge C. Olsen, Øivind Asak, Ingrid P. Berset, Ingrid M. Blomgren, Katrine Dvergsnes, Jon Florholmen, Svein O. Frigstad, Magne Henriksen, Jon Hagfors, Gert Huppertz-Hauss, Espen A. Haavardsholm, Rolf A. Klaasen, Bjørn Moum, Geir Noraberg, Ulf Prestegård, Jan H. Rydning, Liv Sagatun, Kathrine A. Seeberg, Roald Torp, Cecilia Vold, David J. Warren, Carl M. Ystrøm, Knut E. A. Lundin, Tore Kvien, Jørgen Jahnsen
Cite DOI
Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply
Kristin K. Jørgensen, Knut E. Lundin, Inge C. Olsen, Tore K. Kvien, Jørgen Jahnsen
Cite DOI
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
BACKGROUND: TNF inhibitors have improved treatment of Crohn’s disease, ulcerative colitis, spondyloarthritis, rheumatoid …
Kristin K. Jørgensen, Inge C. Olsen, Guro L. Goll, Merete Lorentzen, Nils Bolstad, Espen A. Haavardsholm, Knut E. A. Lundin, Cato Mørk, Jørgen Jahnsen, Tore K. Kvien, NOR-SWITCH study group
Cite DOI